TUESDAY, June 1, 2004 (HealthDayNews) -- The U.S. Food and Drug Administration has approved the Indevus Pharmaceuticals drug Sanctura (trospium chloride) for overactive bladder, a condition that affects some 33 million Americans.
The medication belongs to a class of compounds known as muscarinic receptor antagonists, which relax muscle tissue in the bladder and lessen bladder contractions. Approval was granted following clinical trials in the United States and Europe involving about 3,000 people, Indevus said in a statement.
The most frequently reported side effects include dry mouth and constipation. Most people who have overactive bladder are over age 60, and Sanctura appears to have fewer drug-to-drug interactions than previously approved medications that are common to this age group, the company statement said.
The drug is expected to be available in the United States in the third quarter of this year, Indevus said.
To learn more about overactive bladder, visit the National Kidney and Urologic Diseases Information Clearinghouse.